CardioVascular BioTherapeutics, Inc. (OTC:CVBT.PK) is a biopharmaceutical company focused on developing protein drug candidates to be used in the treatment of cardiovascular disease, the worldwide leading cause of death. The Company’s stock which had traded on The Over the Counter Bulletin Board (OTCBB) has moved to trading on The Over-the-Counter Pink Sheets (OTC:CVBT.PK) which can be found at www.Pinksheets.com.

The Company is developing injectable and topical formulations of its active pharmacological ingredient (API) to facilitate the growth of new blood vessels (angiogenesis) in the heart, tissues and organs that have been compromised by impaired blood supply (hypoxia, ischemia). The Company’s API contains FGF-1(141) a human protein manufactured using a proprietary technology. FGF-1 stimulates the growth and proliferation of the three main cell types of blood vessels; endothelial cells, smooth muscles cells and pericytes.

The Company’s lead drug candidate successfully completed initial clinical trials in Germany during the 1990s, with no drug-related adverse events and a statistically significant increase in localized blood vessel growth (and perfusion) both in patients also receiving coronary by-pass procedures and in patients with severe coronary heart disease (CHD) receiving FGF-1, as the sole therapy. Enrollment and treatment has been completed in an FDA authorized Phase I study with CVBT-141A, administered via injection in severe CHD patients. The protocol design for the Phase II trial (CVBT-141H) has been approved by the FDA and is planned to initiate in 2008.

CardioVascular BioTherapeutics, Inc. is committed to conducting additional clinical trials to establish the positive effect of FGF-1(141) aimed at improving the quality of life for those suffering from heart disease, stroke, diabetic wounds, or peripheral artery disease, and pledges to continue exploration for additional applications of FGF-1.